P.S.K. Biosciences was launched in 2021, originating as a specialized drug delivery platform team within Simcere Pharmaceutical Group. With strategic investment from Lenovo Capital and support from local government grants, the company has become an independent entity focused on pioneering exosome-based therapeutics.

• We specialize in tissue-specific drug delivery using engineered exosomes, with a core emphasis on overcoming the blood-brain barrier (BBB). Our platform enables effective loading of siRNA and mRNA into exosomes through advanced genome editing technologies. We have achieved breakthroughs in both drug encapsulation and scalable manufacturing of exosome-based shRNA/mRNA therapeutics, addressing critical industry challenges.

• We are expanding treatment horizons with our proprietary library of human mesenchymal stem cell-derived exosome (MSC-exo) subpopulations, tailored for specific indications including POI, IPF, IBD, Alzheimer's disease, stroke, and Parkinson's disease. These uniquely characterized exosome subgroups offer enhanced therapeutic efficacy and create distinct opportunities for differentiated innovation.